ViMRT
}  
 
Home   
< Docs   

 HIV mutation literature information.


  Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
 PMID: 28328546       2017       Journal of acquired immune deficiency syndromes (1999)
Result: Two studies reported sequencing the integrase gene in CSF; N155H, L74I, and Q148R mutations were observed as single mutations in the integrase gene, and Y143C was observed in combination with T66I.
Discussion: Three CSF integrase mutations were identified in CSF (N155H, Y143C, and Q148R).


  Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.
 PMID: 28369593       2017       The Journal of antimicrobial chemotherapy
Abstract: After >6 months on dolutegravir therapy, three patients with baseline N155H experienced viral rebound.
Abstract: For raltegravir-experienced individuals, the resistance mutation profile in 9 of 10 viraemic patients was as follows: N155H + A153G/S (four); Y143G + A153S (two); Q148R + G140A/S (two); and Y143C + Q91R (one).
Abstract: In two of them N155H was replaced by Q148K/R and in another by G118R.


  The R263K Dolutegravir Resistance-Associated Substitution Progressively Decreases HIV-1 Integration.
 PMID: 28377526       2017       mBio
Introduction: In addition, treatment failure in such individuals was associated with the presence of various RAL/EVG resistance substitutions that predated DTG use, most notably at positions Q148 and N155H.


  Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors.
 PMID: 29137637       2017       Virology journal
Method: Major INSTI resistance mutations (T66I, E92Q, F121Y, Y143CHR, S147G, Q148HKR, N155H) that confer substantial phenotypic resistance to at least one of the currently approved INSTI as well as minor INSTI resistance mutations (T66AK, L74 M, E92G, T97A, E138AK, G140AS, R263K) that increase INSTI resistance and/or viral


  HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters.
 PMID: 28472323       2017       The Journal of antimicrobial chemotherapy
Abstract: With elvitegravir, large cluster variants more rapidly acquired first mutations (T66I,
Introduction: Dolutegravir is far less prone to the development of resistance in first-line therapy with isolated reported cases of the emergence of R263K, N155H or G118R.
Introduction: Resistance to elvitegravir and raltegravir occurs via several mutational pathways, including: (i) N155H or G140A/G148RHQ pathways conferring raltegravir and elvitegravir cross-resistance; (ii) T66I or E92Q/G elvitegravir-specific pathways; or (iii) the Y143R/H/C raltegravir-specific resistance pathway.


  Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
 PMID: 28923862       2017       Antimicrobial agents and chemotherapy
Abstract: In both single and multiple rounds of HIV-1 infections, BIC remained active against the Y143R, N155H, R263K, R263K/M50I, and R263K/E138K mutants (<=4-fold increase in EC50).
Abstract: In single cycle SIV infections, none of the E92Q, T97A, Y143R, or N155H substitutions had a significant effect on susceptibility to BIC (<=4-fold increase in EC50), whereas G118R and R263K conferred ~14-fold and ~6-fold increases in EC50, respectively.


  Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice.
 PMID: 28637235       2017       The Journal of antimicrobial chemotherapy
Abstract: The virus from this mouse had mutations E138K, G140S, Q148H, N155H and S230R, was highly resistant to both raltegravir (EC50 of >1000 nM) and dolutegravir (EC50 of 550 nM), and replicated to levels similar to those of control viruses in PBMCs.


  Impact of HIV-1 Integrase L74F and V75I Mutations in a Clinical Isolate on Resistance to Second-Generation Integrase Strand Transfer Inhibitors.
 PMID: 28533248       2017       Antimicrobial agents and chemotherapy
Abstract: Addition of L74F V75I to N155H or G140S Q148H increased resistance levels to the second-generation INSTIs dolutegravir (>385- and 100-fold, respectively) and cabotegravir (153- and 197-fold, respectively).


  Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
 PMID: 28891788       2017       HIV clinical trials
Method: Primary INSTI-R substitutions assessed were T66A/I/K, E92G/Q, T97A, Y143C/H/R, S147G, Q148H/K/R, and N155H/S in IN.
Result: At a 2% cutoff, E92G and N155H were observed in 1 participant each, and S147G was observed in 2 participants, at low percentages ranging from 2.1% to 3.7% (mutational viral loads: E92G, 920 copies/mL; S147G, 430 copies/mL and 490 copies/mL; N155H, 770 copies/mL).
Result: Four other EVG


  Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naive HIV patients.
 PMID: 27432606       2016       The Journal of antimicrobial chemotherapy
Abstract: N155H mutation was detected at failure in one patient.



Browser Board

 Co-occurred Entities




   Filtrator